Showing results (21-30 of 109) with videos related to
Sort By:
Pageof 11
Brain Research|October 2, 1992
A single restraint stress exposure potentiates analgesia induced by intrathecally administered DAGOD J Calcagnetti, J L Stafinsky, T CrispPharmacology, Biochemistry, and Behavior|July 1, 1987
Quaternary naltrexone reveals the central mediation of conditional opioid analgesiaD J Calcagnetti, F J Helmstetter, M S FanselowBrain Research|March 15, 1988
Peripheral versus intracerebroventricular administration of quaternary naltrexone and the enhancement of Pavlovian conditioningM S Fanselow, D J Calcagnetti, F J HelmstetterThe Journal of Pharmacology and Experimental Therapeutics|September 1, 1989
Role of mu and kappa opioid receptors in conditional fear-induced analgesia: the antagonistic actions of nor-binaltorphimine and the cyclic somatostatin octapeptide, Cys2Tyr3Orn5Pen7-amideM S Fanselow, D J Calcagnetti, F J HelmstetterPharmacology, Biochemistry, and Behavior|February 1, 1989
Delta opioid antagonist, 16-Me cyprenorphine, selectively attenuates conditional fear- and DPDPE-induced analgesia on the formalin testM S Fanselow, D J Calcagnetti, F J HelmstetterBrain Research|February 19, 1990
Stress-induced tolerance to delta receptor agonist DPDPE and selectivity of the irreversible delta-ligand, DALCED J Calcagnetti, W D Bowen, S G HoltzmanPharmacology, Biochemistry, and Behavior|August 1, 1992
Direct microinjection of cathinone into the rat brain produces discriminative stimuliM D Schechter, J B Schechter, D J CalcagnettiPharmacology, Biochemistry, and Behavior|January 1, 1990
Centrally administered opioid antagonists, nor-binaltorphimine, 16-methyl cyprenorphine and MR2266, suppress intake of a sweet solutionD J Calcagnetti, R L Calcagnetti, M S FanselowPharmacology, Biochemistry, and Behavior|September 1, 1990
Pharmacological profile of the potentiation of opioid analgesia by restraint stressD J Calcagnetti, S W Fleetwood, S G HoltzmanBehavioral Neuroscience|June 1, 1989
Modulation of appetitively and aversively motivated behavior by the kappa opioid antagonist MR2266M S Fanselow, D J Calcagnetti, F J HelmstetterPageof 11